SLC5A2 and lobular neoplasia: Patients with LN and antineutrophil cytoplasmic autoantibodies-associated vasculitis were included in the EMPA-Kidney trial, which compared the SGLT2 inhibitor empagliflozin vs placebo, but the results from this dedicated subgroup of patients are not yet published.